Prognosis of the bradycardia pacemaker recipient assessed at first implantation: a nationwide cohort study

Udo, Erik O.; Hemel, Norbert M. van; Zuithoff, Nicolaas P.A.; Doevendans, Pieter A.; Moons, Karel G.M.

doi:10.1136/heartjnl-2013-304445

Cited by 29 publications

(49 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, survival for recipients without CVD matched that of the general population. This was also the case for the oldest old (octogenarians and nonagenarians) [3,4]. Similar findings for elderly patients without symptomatic heart disease were reported in earlier decades from a small study from Olmsted County, Minnesota [5], and survival for agesex-and comorbidity-matched Taiwanese nonagenarians implanted with PPMs from 2001-2012 was no worse than for controls [6].…”

Section: Introductionsupporting

confidence: 83%

“…Similar findings for elderly patients without symptomatic heart disease were reported in earlier decades from a small study from Olmsted County, Minnesota [5], and survival for agesex-and comorbidity-matched Taiwanese nonagenarians implanted with PPMs from 2001-2012 was no worse than for controls [6]. Commonly identified factors associated with increased risk for death after PPM implantation include older age, CVD, heart failure (HF) and cardiomyopathy [1][2][3][4][5][6].…”

Section: Introductionsupporting

confidence: 74%

“…equivalent to the general population), in the absence of comorbidities. This finding is supported by similar results from the Netherlands, where survival to a minimum of 3.3 years for patients who did not have CVD was estimated to be equivalent to age-and sex-matched controls, (patients with serious conditions such as cancer, and immune and degenerative diseases at implantation having been excluded from the analysis) [3].…”

Section: Discussionsupporting

confidence: 54%

“…'Years of potential life lost' up to age 65 or 75 years is a frequently used population health measure as a reference against which to estimate premature deaths [7] but is not useful for studies of PPM outcomes as the average age of patients requiring a first PPM exceeds 75 years in developed countries [3,8]. We selected 'expected (remaining) years of life lost' (EYLL), based on the complete expectation of life, to measure International Journal of Cardiology 190 (2015) 42-46 ☆ Each of the authors takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation and has given final approval to the submitted manuscript.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Life expectancy after implantation of a first cardiac permanent pacemaker (1995–2008): A population-based study

Bradshaw

Stobie

Knuiman

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Introductionsupporting

confidence: 83%

Section: Introductionsupporting

confidence: 74%

Section: Discussionsupporting

confidence: 54%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Life expectancy after implantation of a first cardiac permanent pacemaker (1995–2008): A population-based study

Bradshaw

Stobie

Knuiman

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…In studies concerning large groups of patients, Udo et al presented a study of 1517 patients and their observation within the period [2003][2004][2005][2006][2007]. In this study, the survival rate was between 81% and 69 % [15]. In many studies, the researchers attempted to determine the factors that decide about the survival of a patient after permanent pacemaker implantation.…”

Section: Discussionmentioning

confidence: 97%

Medium-term prognosis of survival and hospitalization of patients after permanent pacemaker implantation based on BNP, high-sensitivity troponin T, and left atrium volume index

Kaziród-Wolski¹,

Sielski²,

Grabowska³

2017

View full text Add to dashboard Cite

Key words: cardiac pacing, B-type natriuretic peptide, left atrial volume index.Słowa kluczowe: stymulacja serca, peptyd natriuretyczny typu B, indeks objętości lewego przedsionka. AbstractIntroduction: Determination of predictors of survival and hospitalization can optimise a medical care of patient with permanent pacemaker. Aim of the research: Use of the B-type natriuretic peptide (BNP), high-sensitivity troponin T (TnT hs), and left atrial volume index (LAVI) to control survival and hospitalizations due to cardiovascular causes in patients after pacemaker implantation. Material and methods:The study covered a sample of 123 patients qualified for pacemaker implantation. During 23-month observation, cyclic BNP, TnT hs and LAVI examinations were performed. Mortality and hospitalization rate in groups with normal and elevated values were assesed using Kaplan-Meier curves. Results: A statistical relationship was observed between survival and increased initial BNP plasma level (log-rank test = 2.11, p < 0.05). Significantly higher frequency of hospitalizations was observed with a higher initial BNP plasma level (log-rank test = 2.01, p < 0.05). No statistically significant relationships were found between the TnT hs concentration and the duration of survival and hospitalizations. A strong tendency was confirmed (p < 0.10) towards a higher probability of the survival of patients with low values of LAVI, compared to patients with high values of LAVI. Conclusions: Results of the study conducted in regional centre (over 1000 implantations per year) confirmed that BNP peptide is an important indicator of survival and hospitalization due to cardiovascular causes after permanent pacemaker implantation. From among the 3 parameters examined: BNP, TnT hs LAVI, only BNP peptide and LAVI may be justified in the evaluation of patients after pacemaker implantation. Determination of BNP for evaluation medium-term prognosis of survival and hospitalization may be considered during routine pacemaker control visit.

show abstract

Impact of prior permanent pacemaker on long‐term clinical outcomes of patients undergoing percutaneous coronary intervention

Zhang

Yang

et al. 2016

Clinical Cardiology

View full text Add to dashboard Cite

Background The impact of permanent pacemaker (PPM) on long‐term clinical outcomes of patients undergoing percutaneous coronary intervention (PCI) has not been studied. Hypothesis PPM may increase heart failure (HF) burden on patients undergoing PCI. Methods We recruited consecutive patients undergoing PCI and carried out a nested case–control study. Patients with confirmed PPM undergoing first PCI were identified and matched by age and sex in 1:1 fashion to patients without PPM undergoing first PCI. Clinical data were collected and analyzed. The primary endpoint outcomes were all‐cause mortality and hospitalization for HF. Results The final analysis included 156 patients. The mean follow‐up period was 4.6 ± 2.9 years. The overall all‐cause mortality was 21.15%, without significant difference between the 2 groups (21.79% vs 20.51%; P = 0.85). However, the rate of HF‐related hospitalization was significantly higher in patients with PPM than in controls (26.92% vs 10.26%; P = 0.008). After adjustment for hypertension, type 2 diabetes mellitus, hyperlipidemia, chronic kidney disease, stroke, left ventricular ejection fraction, brain natriuretic peptide, and acute coronary syndrome (ACS), PCI patients with PPM were still associated with a greater hospitalization rate for HF (odds ratio: 4.31, 95% confidence interval: 0.94‐19.80, P = 0.061). Further analysis in the ACS subgroup showed VVI‐mode pacing enhanced the risk for HF‐associated hospitalization (adjusted odds ratio: 8.27, 95% confidence interval: 1.37‐49.75, P = 0.02). Conclusions PPM has no effect on all‐cause mortality in patients undergoing first PCI but significantly increases the HF‐associated hospitalization rate, especially in ACS patients.

show abstract

Prognosis of the bradycardia pacemaker recipient assessed at first implantation: a nationwide cohort study

Abstract: ClinicalTrials.gov Identifier: NCT00135174.

Cited by 29 publications

References 30 publications

Life expectancy after implantation of a first cardiac permanent pacemaker (1995–2008): A population-based study

Life expectancy after implantation of a first cardiac permanent pacemaker (1995–2008): A population-based study

Medium-term prognosis of survival and hospitalization of patients after permanent pacemaker implantation based on BNP, high-sensitivity troponin T, and left atrium volume index

Impact of prior permanent pacemaker on long‐term clinical outcomes of patients undergoing percutaneous coronary intervention

Contact Info

Product

Resources

About